David Fuller
Chief Tech/Sci/R&D Officer bij DIMERIX LIMITED
Vermogen: 1 759 $ op 31-03-2024
Profiel
David Fuller is currently the Chairman of EpiAxis Therapeutics Pty Ltd.
He also holds the position of Non-Executive Director at AdAlta Ltd.
since 2020 and will be the Chief Medical Officer at Dimerix Ltd.
starting in 2023.
Previously, he was the Chief Medical Officer at Race Oncology Ltd.
from 2021 to 2022.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
RACE ONCOLOGY LTD.
0.00% | 30-06-2023 | 1 899 ( 0.00% ) | 1 759 $ | 31-03-2024 |
Actieve functies van David Fuller
| Bedrijven | Functie | Begin |
|---|---|---|
| ADALTA LIMITED | Director/Board Member | 22-07-2020 |
| DIMERIX LIMITED | Chief Tech/Sci/R&D Officer | 23-10-2023 |
EpiAxis Therapeutics Pty Ltd.
 EpiAxis Therapeutics Pty Ltd. BiotechnologyHealth Technology EpiAxis Therapeutics Pty Ltd. engages in biotechnology company. It pursuing a preclinical and clinical drug development program directed at the prevention of metastatic disease by targeting the pivotal enzyme system controlling the proliferation of cancer stem cells. The company was founded by Jeremy Chrisp and Sudha Rao and is headquartered in Canberra, Australia. | Chairman | - |
Eerdere bekende functies van David Fuller
| Bedrijven | Functie | Einde |
|---|---|---|
| RACE ONCOLOGY LIMITED | Chief Tech/Sci/R&D Officer | 11-11-2022 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| DIMERIX LIMITED | Health Technology |
| ADALTA LIMITED | Health Technology |
| RACE ONCOLOGY LIMITED | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
EpiAxis Therapeutics Pty Ltd.
EpiAxis Therapeutics Pty Ltd. BiotechnologyHealth Technology EpiAxis Therapeutics Pty Ltd. engages in biotechnology company. It pursuing a preclinical and clinical drug development program directed at the prevention of metastatic disease by targeting the pivotal enzyme system controlling the proliferation of cancer stem cells. The company was founded by Jeremy Chrisp and Sudha Rao and is headquartered in Canberra, Australia. | Health Technology |
